A leukemia flow cytometry panel analyzes proteins on and inside blood-forming cells to identify abnormal cell populations and determine their lineage and stage of maturation. It is one of the fastest ways to distinguish acute myeloid leukemia (AML), B- or T-lymphoblastic leukemia, mixed-phenotype acute leukemia, and many chronic leukemias, but it does not work alone. The final diagnosis usually combines flow cytometry with the blood count, blood smear, bone marrow morphology, chromosome studies, fluorescence in situ hybridization (FISH), and molecular testing.
Results are reported as an immunophenotype: a pattern of markers such as CD34, CD117, myeloperoxidase (MPO), CD13, CD33, CD19, CD10, CD79a, cytoplasmic CD3, terminal deoxynucleotidyl transferase (TdT), and others. No single marker proves most leukemias. The pattern, marker intensity, percentage of abnormal cells, and relationship to normal maturation are what matter. A well-interpreted panel can rapidly narrow the diagnosis, guide urgent confirmatory tests, and establish a baseline for later measurable residual disease testing.
- What it measures: Flow cytometry measures combinations of cell-surface and intracellular markers on thousands to millions of individual cells, revealing abnormal lineage and maturation patterns.
- What an abnormal result means: An abnormal immunophenotype supports a clonal or leukemic population, but the exact leukemia type usually requires correlation with morphology and genetic findings.
- What “blasts” mean: Blasts are immature precursor cells; their percentage is important, but some genetically defined leukemias can be diagnosed even when classic blast thresholds are not met.
- Preparation: No fasting is usually required. The key requirement is a fresh, properly collected blood, bone marrow, or other specimen with enough viable cells.
- Why follow-up testing matters: Flow findings often trigger targeted FISH, chromosome, or molecular tests that can confirm the subtype and identify treatment-relevant abnormalities.
Table of Contents
- What a leukemia flow cytometry panel shows
- Key cell markers and how lineage is assigned
- Blasts, abnormal maturation, and immunophenotype
- Common flow patterns by leukemia type
- How the test is performed and reported
- Limits, pitfalls, and follow-up testing
- Questions to ask about your results
What a leukemia flow cytometry panel shows
Flow cytometry answers a practical question: what kinds of cells are present, and do any of them behave immunophenotypically like leukemia? A laboratory labels cells with fluorescent antibodies that bind specific antigens. As cells pass through lasers one at a time, the instrument records light scatter and fluorescence. Software then displays groups of cells according to size, internal complexity, and marker expression.
The test can detect an abnormal population even when the cells do not look dramatically different by microscope. It can also separate cells that appear similar morphologically but belong to different lineages. That matters in acute leukemia, where treatment differs substantially between AML, B-lymphoblastic leukemia/lymphoma, and T-lymphoblastic leukemia/lymphoma.
A flow report may describe:
- the percentage of abnormal cells among analyzed nucleated cells;
- whether the cells are immature or mature;
- which markers are positive, negative, dim, bright, partial, or heterogeneous;
- whether expression is aberrant for that lineage or stage of maturation;
- whether the population has B-cell, T-cell, myeloid, monocytic, megakaryocytic, or mixed features; and
- whether the pattern is suitable for future disease monitoring.
Flow cytometry is especially useful when leukemia is suspected because it can return lineage information quickly. Yet classification has moved beyond a purely immunophenotypic system. Modern AML and ALL diagnoses integrate genetics because specific gene fusions or mutations can define disease entities, alter prognosis, and guide therapy.
For broader molecular context, a hematologic cancer biomarker panel may include tests that complement the cell-level information from flow cytometry. Once treatment begins, the same abnormal phenotype may also become one part of MRD testing for leukemia.
Key cell markers and how lineage is assigned
The meaning of a marker depends on the other markers around it. A cell can express an antigen commonly associated with another lineage, so laboratories use combinations rather than single-marker shortcuts.
| Marker or group | Typical interpretation | Important nuance |
|---|---|---|
| CD34, TdT | Immaturity or precursor phenotype | Not all leukemic blasts express CD34 or TdT, and some normal precursors do. |
| MPO | Strong evidence of myeloid lineage | Intensity and distribution matter, especially in mixed-lineage cases. |
| CD13, CD33, CD117 | Common myeloid-associated markers | They support but do not independently prove myeloid lineage. |
| CD64, CD14, CD11c, CD36 | Monocytic differentiation | Panels usually assess more than one monocytic marker. |
| CD19, CD22, CD79a, CD10 | B-lineage or B-cell precursor differentiation | Marker strength and the full pattern are used for lineage assignment. |
| Cytoplasmic or surface CD3 | T-lineage | Cytoplasmic CD3 is particularly important in immature T-lineage disease. |
| CD41, CD61, CD42b | Megakaryocytic differentiation | Useful when acute megakaryoblastic leukemia is considered. |
| CD45 | Leukocyte marker and gating aid | Blasts often show relatively dim CD45 compared with mature lymphocytes. |
Myeloid lineage
AML commonly shows combinations of CD13, CD33, CD117, MPO, and variable CD34 and HLA-DR. Some subtypes have distinctive patterns. Acute promyelocytic leukemia (APL), for example, often has strong CD33 with absent or low HLA-DR and CD34, but flow alone cannot establish APL. Suspected APL is a medical urgency because coagulopathy can become life-threatening, so rapid testing for PML::RARA is required. A dedicated PML-RARA fusion test addresses that defining abnormality.
B- and T-lineage
B-lymphoblasts often express CD19, CD22, CD79a, CD10, TdT, and sometimes CD34, while mature B-cell leukemias show surface immunoglobulin and a more mature antigen pattern. T-lymphoblasts typically express cytoplasmic CD3 and TdT with variable CD1a, CD2, CD5, CD7, CD4, and CD8. Mature T-cell leukemias are assessed for abnormal losses, gains, or intensity patterns among T-cell markers.
Lineage assignment in ambiguous leukemia follows strict criteria. A cell that is merely CD7-positive is not automatically T-lineage, and CD19 expression by itself may not be enough to classify a myeloid leukemia as B-lineage. The laboratory evaluates marker strength, combinations, and genetic data before calling mixed-phenotype acute leukemia.
Blasts, abnormal maturation, and immunophenotype
A “blast percentage” is important, but it is not the entire diagnosis. Blasts are immature hematopoietic cells. In many acute leukemias they accumulate because malignant cells fail to mature normally. Flow cytometry can estimate the abnormal blast population, but this percentage may differ from the microscope count because each method samples and defines cells differently.
One reason is specimen quality. A bone marrow aspirate can become diluted with peripheral blood, lowering the apparent blast proportion. Fragile blasts may also be lost during specimen processing. Conversely, flow gates may include or exclude cells differently from a manual differential. The hematopathologist reconciles these data rather than expecting identical numbers.
Modern classifications also recognize genetically defined AML categories in which a rigid 20% blast cutoff is not always required. This is why an apparently “low” blast percentage cannot be interpreted without the genetic and morphologic context.
What makes an immunophenotype abnormal?
A leukemic immunophenotype may be abnormal in several ways:
- Asynchronous expression: markers from different maturation stages appear together in a way normal cells usually do not.
- Cross-lineage expression: myeloid blasts may aberrantly express a lymphoid-associated marker, or vice versa.
- Abnormal intensity: a marker can be much brighter or dimmer than expected.
- Loss of expected markers: a population lacks an antigen normally present at that maturation stage.
- Uniformity: cells that should show a maturation continuum instead form a tight, relatively uniform cluster.
CD34 is a useful example. It marks many hematopoietic progenitors and many leukemic blasts, but it is neither specific for leukemia nor present in every leukemia. A CD34 result therefore makes sense only within the complete phenotype.
The same principle applies to treatment monitoring. A diagnostic phenotype can help identify residual leukemia later, but therapy may alter antigen expression. High-quality MRD laboratories therefore look both for the original leukemia-associated immunophenotype and for populations that differ from normal maturation.
Common flow patterns by leukemia type
Flow patterns can strongly suggest a category, but they are not substitutes for the complete classification workup.
| Suspected leukemia | Common flow features | Typical next steps |
|---|---|---|
| AML | MPO and/or myeloid markers such as CD13, CD33, CD117; variable CD34 and HLA-DR | Karyotype, AML FISH where appropriate, and molecular testing for defining/prognostic variants |
| B-lymphoblastic leukemia | CD19 with precursor markers such as TdT and often CD10, CD22, CD79a, variable CD34 | Genetic testing for B-ALL defining lesions, including BCR::ABL1 and other fusions |
| T-lymphoblastic leukemia | Cytoplasmic CD3 with TdT and variable CD1a, CD2, CD5, CD7, CD4, CD8 | Cytogenetic and molecular classification; assessment of high-risk features |
| CLL | Clonal B cells with characteristic coexpression patterns, often CD5 and CD23 with dim B-cell antigen intensity | Confirm mature B-cell clonality and perform prognostic/predictive studies when clinically indicated |
| Hairy cell leukemia | Mature clonal B-cell population with a characteristic combination that can include CD11c, CD25, CD103, and CD123 | Morphology and molecular confirmation, commonly including BRAF assessment |
| Mixed-phenotype acute leukemia | Blasts meet stringent criteria for more than one lineage | Genetic testing and expert hematopathology review are essential |
A BCR::ABL1 abnormality illustrates why genetics cannot be skipped. It may define chronic myeloid leukemia or occur in acute lymphoblastic leukemia and, in specific circumstances, AML. A BCR-ABL1 test identifies the fusion directly and can later be used for molecular monitoring.
Likewise, NPM1 mutation status can help define AML and has important prognostic and MRD implications. The NPM1 mutation test provides information that a surface-marker panel cannot supply.
How the test is performed and reported
The specimen may be peripheral blood, bone marrow aspirate, cerebrospinal fluid, or another fluid or tissue suspension, depending on the clinical question. For suspected leukemia, blood and bone marrow are most common. Fasting is generally unnecessary. The main preanalytic concern is obtaining enough viable cells and getting the sample to the flow laboratory promptly.
The laboratory first evaluates light scatter and broad markers such as CD45 to identify major cell compartments. It then applies combinations of fluorescent antibodies. Modern panels may measure many markers simultaneously, allowing the analyst to compare abnormal cells against normal maturation pathways rather than relying on a single two-marker plot.
A report often contains four layers of information:
- Specimen and quality: source, viability, cellularity, or limitations such as low cell count.
- Abnormal population size: an estimate of the percentage of analyzed cells with the suspicious phenotype.
- Immunophenotype: positive and negative markers with comments on intensity or heterogeneity.
- Interpretation: the lineage and differential diagnosis, plus recommended correlation with morphology, cytogenetics, or molecular tests.
A result may say, for example, that an abnormal myeloid blast population represents 35% of white cells and expresses CD34, CD117, CD13, CD33, and MPO with aberrant CD7. That statement supports AML, but it still does not provide the final WHO or ICC subtype. The genetic workup could reveal a defining fusion or mutation that changes the disease name and clinical implications.
Timing varies by institution and specimen. Flow cytometry itself can generate data rapidly, but the final integrated pathology report may take longer because chromosome and molecular results return on different schedules. If clinicians suspect a time-critical entity such as APL, they do not wait for the entire panel to finish before ordering urgent confirmatory testing.
Limits, pitfalls, and follow-up testing
The biggest mistake is treating flow cytometry as a stand-alone yes/no leukemia test. It is powerful because it is multiparametric, but several limitations can affect interpretation.
Specimen dilution can underestimate marrow disease. Low viability may selectively remove fragile abnormal cells. Prior treatment, including steroids or targeted antibodies, can change marker expression. Very small populations require careful distinction from normal precursors, regenerating marrow, or therapy-related changes. Some leukemias also have phenotypes that overlap with other entities.
Flow cytometry is less informative for abnormalities that are fundamentally genetic. It may suggest a genotype, but a characteristic pattern is not proof. The appropriate confirmatory test may be PCR, FISH, conventional cytogenetics, or next-generation sequencing.
Follow-up studies commonly include:
- complete blood count and peripheral smear review;
- bone marrow morphology and biopsy when indicated;
- chromosome analysis and targeted FISH;
- molecular panels for mutations and gene fusions;
- disease-specific tests for actionable or defining abnormalities; and
- MRD testing after therapy using flow cytometry, PCR, or next-generation sequencing as appropriate.
The combination also prevents false reassurance. A “negative” flow study means no abnormal population was detected under that assay’s conditions; it does not always exclude leukemia. Disease can be below the detection limit, absent from the sampled site, or difficult to distinguish because of sample quality or treatment effects.
Conversely, a small abnormal population does not automatically mean overt acute leukemia. The clinical setting, count, morphology, clonality, genetics, and previous treatment history determine its meaning.
Questions to ask about your results
A flow report is dense, so focus first on the interpretive conclusion rather than trying to decode every CD marker. Useful questions include:
- Was an abnormal cell population found, and what percentage of the analyzed cells did it represent?
- What lineage does the abnormal population most strongly support: myeloid, B-cell, T-cell, or mixed?
- Does the report call the cells blasts, mature lymphoid cells, or another population?
- Was the specimen adequate, or could dilution, low viability, or low cell number limit sensitivity?
- Which chromosome, FISH, or molecular tests are still pending?
- Does the phenotype suggest any urgent diagnosis that needs rapid confirmation?
- Will this phenotype be useful as a baseline for later MRD testing?
If the report uses phrases such as “findings are suspicious for,” “consistent with,” or “cannot exclude,” that wording often reflects a real diagnostic boundary rather than uncertainty from poor testing. Hematologic malignancies are intentionally classified using multiple data types.
Symptoms also matter. Seek prompt medical evaluation for significant bleeding, new shortness of breath, chest pain, fainting, high fever, rapidly worsening weakness, or neurologic changes. People with very low blood counts or suspected acute leukemia may need urgent care even before every classification test is final.
The central point is simple: a leukemia flow cytometry panel tells clinicians what the abnormal cells look like biologically, while genetic and morphologic tests determine exactly what disease those cells represent. Used together, these methods provide a faster and more reliable diagnosis than any one test alone.
Why flow results can change after treatment
Treatment can alter both the number and appearance of leukemia cells. Steroids, chemotherapy, targeted therapy, or an earlier transfusion may reduce abnormal cells in the sampled blood or marrow, while regenerating normal precursors can temporarily look unusual. For that reason, a post-treatment flow result should be compared with the original diagnostic phenotype whenever possible. The laboratory may use the known leukemia-associated immunophenotype as one strategy while also searching broadly for cells that differ from normal maturation.
Timing and specimen quality matter just as much as marker selection. A marrow aspirate diluted with peripheral blood can underestimate residual disease, and a sample with poor cell viability may lose fragile abnormal populations. If the clinical picture and flow result disagree, repeating marrow sampling or using a complementary molecular method may be more informative than assuming either result is definitive.
References
- Acute Myeloid Leukemia: Diagnosis and Evaluation by Flow Cytometry 2024 (Review)
- Advances in Acute Myeloid Leukemia Classification, Prognostication and Monitoring by Flow Cytometry 2023 (Review)
- Advances in Flow Cytometry for Mixed Phenotype and Ambiguous Leukemias 2023 (Review)
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms 2022 (Review)
- Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel 2024 (Guideline)
Disclaimer
This article is for general education and is not a substitute for diagnosis or treatment by a hematologist or hematopathologist. Flow cytometry findings must be interpreted with the specimen quality, blood and marrow morphology, clinical history, and genetic studies. Seek urgent medical care for severe bleeding, breathing difficulty, fainting, high fever, or rapidly worsening symptoms.
